PPARG and metastatic malignant neoplasm: Increased in the progression from PanINs to metastatic cancer; downregulation of cell cycle regulators including cyclin D1, p16, PTEN and the upregulation of p27, p53, p21, cyclin B1, PPARγ, and TGF-β; resistant to chemotherapy